Icons / Logo / Facebook Created with Sketch. Icons / Logo / Google Created with Sketch. Icons / Logo / ORCID Created with Sketch. Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Brett Glotzbecker
Harvard University
72Publications
13H-index
930Citations
Publications 72
Newest
Published on Mar 28, 2019in Clinical Infectious Diseases 9.05
Matthew P. Cheng8
Estimated H-index: 8
(Harvard University),
Amanda E Kusztos1
Estimated H-index: 1
(Harvard University)
+ 7 AuthorsFrancisco M. Marty43
Estimated H-index: 43
(Harvard University)
Published on May 20, 2019in Journal of Clinical Oncology 28.25
Houry Leblebjian6
Estimated H-index: 6
(Harvard University),
Megan Duperrault (Harvard University)+ 7 AuthorsDavid Dougherty (Harvard University)
Published on Mar 15, 2019in Journal of Cancer Education 1.69
Jackie Foster1
Estimated H-index: 1
(National Marrow Donor Program),
Heather Moore2
Estimated H-index: 2
(National Marrow Donor Program)
+ 10 AuthorsElizabeth Murphy79
Estimated H-index: 79
(National Marrow Donor Program)
Hematopoietic cell transplantation (HCT) is a complex and potentially life-threatening treatment option for patients with hematologic malignant and non-malignant diseases. Advances have made HCT a potentially curative treatment option for patients 65 years of age and older (older patients), and patient education resources should be adapted to meet their needs. To better understand the information needs of older patients and their caregivers for HCT treatment decision-making, the National Marrow ...
Published on Mar 1, 2019in Biology of Blood and Marrow Transplantation 3.60
Sarah Nikiforow18
Estimated H-index: 18
(Harvard University),
Nancy Berliner36
Estimated H-index: 36
(Brigham and Women's Hospital)
+ 12 AuthorsMahasweta Gooptu4
Estimated H-index: 4
(Harvard University)
Introduction HLH has historically been considered a pediatric disease. There are limited prospective data for adults with HLH, particularly on management during and outcomes after allogeneic HSCT. Following the CTN1204 study of HSCT in pediatric HLH, this retrospective analysis sets a benchmark for adult-onset HLH. Subjects We identified 20 patients, median 45yo (21-72), who underwent RIC HSCT for HLH since 2010. 5 (25%) had a malignancy, 3 (15%) a rheumatologic diagnosis, and 3 (15%) a viral pr...
Published on Feb 1, 2019in American Journal of Therapeutics 1.13
Prabhsimranjot Singh5
Estimated H-index: 5
,
Kristen Lʼ Esperance + 3 AuthorsBrett Glotzbecker13
Estimated H-index: 13
Published on Jan 1, 2019in Biology of Blood and Marrow Transplantation 3.60
Lindsey E. Roeker6
Estimated H-index: 6
(MSK: Memorial Sloan Kettering Cancer Center),
Haesook T. Kim55
Estimated H-index: 55
(Harvard University)
+ 10 AuthorsJoseph H. Antin99
Estimated H-index: 99
(Brigham and Women's Hospital)
Abstract Hepatic veno-occlusive disease (VOD), or sinusoidal obstruction syndrome (SOS), is a serious complication of hematopoietic stem cell transplantation (HSCT) with mortality in its severe form exceeding 80%. Although the incidence of VOD/SOS has fallen with contemporary transplantation practices, the increasing use of inotuzumab, the return of gemtuzumab, and the popularity of pharmacokinetic-guided high-dose busulfan may impact incidence. Early intervention with defibrotide improves survi...
Published on Nov 26, 2018in Open Forum Infectious Diseases
Amanda E Kusztos1
Estimated H-index: 1
(Harvard University),
Matthew P. Cheng8
Estimated H-index: 8
(Harvard University)
+ 7 AuthorsFrancisco M. Marty43
Estimated H-index: 43
(Harvard University)
Published on Oct 20, 2018in Journal of Clinical Oncology 28.25
Sadiqa Mahmood (Harvard University), Eli Schwamm1
Estimated H-index: 1
(Harvard University)
+ 9 AuthorsJoseph O. Jacobson25
Estimated H-index: 25
(Harvard University)
326Background: The immune checkpoint inhibitors (ICIs) confer a risk of unique inflammatory immune-related adverse events (irAEs), which are highly distinct from the adverse events historically observed with cytotoxic therapy. To develop a strategy for easier identification and mitigation of irAEs, we sought to understand the frequency of ED visits and hospitalizations in 90 days following ICI start by implementing a rapid learning system (RLS). Methods: We convened an Immunotherapy Toxicities M...
Published on Oct 18, 2018in Journal of Oncology Pharmacy Practice 1.83
Elaine Xiang (Harvard University), Jian Ni (Brigham and Women's Hospital)+ 3 AuthorsAnne McDonnell8
Estimated H-index: 8
(Brigham and Women's Hospital)
IntroductionFor multiple myeloma patients who respond to primary therapy, autologous hematopoietic stem cell transplant (HSCT) is considered standard of care with high-dose melphalan for transplant candidates. There are now two different melphalan formulations available, including a propylene glycol containing (PG-MEL) product and a propylene glycol-free (PG-free MEL) product. Although considered bioequivalent, there remains limited literature directly evaluating the adverse events between the t...
Published on Aug 1, 2018in Biology of Blood and Marrow Transplantation 3.60
Mahasweta Gooptu4
Estimated H-index: 4
(Harvard University),
Haesook T. Kim55
Estimated H-index: 55
(Harvard University)
+ 10 AuthorsPrashant Nageshwar1
Estimated H-index: 1
(Harvard University)
Abstract With improvement in transplantation practices in the modern era, nonrelapse mortality (NRM) following allogeneic hematopoietic stem cell transplantation (HSCT) has improved, while disease relapse rates have remained unchanged. Survival outcomes are therefore driven by NRM in the modern era. Myeloablative conditioning (MAC) regimens are used to maximize disease control and facilitate engraftment; however, their use is often limited by toxicity. The commonly used MAC regimens incorporate ...
12345678